titanium dioxide, macrogol 3350, talc, iron oxide yellow)	

9. A pharmaceutical composition according to any one of claims 1 to 8 for use as medicament for the for the treatment of negative or cognitive symptoms in schizophrenia, deficits in social communications and interactions in autism spectrum disorders (ASD), apathy in early Alzheimer's disease (AD), residual symptoms of motivation after a recent major depressive episode, post traumatic stress disorder (PTSD), for the prophylaxis for patients at high risk of schizophrenia and for the treatment of apathy and cognitive deficits in Parkinson's-disease.

10. The use of a pharmaceutical composition according to any one of claims 1 to 8 for the treatment of negative or cognitive symptoms in schizophrenia, deficits in social communications and interactions in autism spectrum disorders (ASD), apathy in early Alzheimer's disease (AD), residual symptoms of motivation after a recent major depressive episode, post traumatic stress disorder (PTSD), for the prophylaxis for patients at high risk of schizophrenia and for the treatment of apathy and cognitive deficits in Parkinson's-disease.

11. A method for the treatment of negative or cognitive symptoms in schizophrenia, deficits in social communications and interactions in autism spectrum disorders (ASD), apathy in early Alzheimer's disease (AD), residual symptoms of motivation after a recent major depressive episode, post traumatic stress disorder (PTSD), for the prophylaxis for patients at high risk of schizophrenia and for the treatment of apathy and cognitive deficits in Parkinson's-disease, comprising the step of administering a pharmaceutical composition according to any one of claims 1 to 8 to a patient in need thereof.

12. A pharmaceutical composition according to any one of claims 1 to 8 which is administered once daily.

~~13. The invention as hereinbefore described.~~